top of page

ANTI-SCARRING GENE THERAPY

Cellastra is Pioneering Scar Prevention
At Tissue Sites after Pulmonary Infections/Fibrosis, Burns, and Surgery
Cellastra is using proprietary AAV Technology to enable targeted production of antiscarring peptides
Now seeking qualified investors and development partners
Please see our Technology section for unique opportunities.
Cellastra News
CELLASTRA INC.
05/07/2025
Cellastra One Page Overview: 🔗
Corporate Presentation: 🔗
CELLASTRA INC.
11/18/2024
Cellastra Appoints Emma Ye to the Executive Team
Young Scientist and Entrepreneur promoted to Scientific Adviser, Communications: 🔗
CELLASTRA INC.
02/06/2024
Cellastra Receives US Patent for Recombinant Gene Vectors Encoded to Regulate Endogenous Production of Anti-Scarring/Adhesion Lactoferrin Biomolecules.
a human lactoferrin protein or a sub-peptide thereof: 🔗
bottom of page